BIOX-101 (Ir-CPI) displays an antithrombotic activity through its interaction with upstream blood coagulation factors (FXIa/FXIIa) of the intrinsic pathway.

Bioxodes has also demonstrated that BIOX-101 decreases neutrophil activation and Neutrophil Extracellular Trap (NET) release. Neutrophils and NETs, networks of extracellular fibers primarily constituted of DNA, are key components of the neuroinflammatory and thrombotic processes encountered in patients with intracerebral hemorrhage (ICH).

Due to its outstanding dual mechanism of action on both coagulation factors and neutrophils, BIOX-101 not only prevents thrombo-inflammatory processes but also represents a promising alternative to current anticoagulants as deficiencies in FXII and FXI protect against thrombosis without causing spontaneous hemorrhage.